Drug Trial Radar · NCT03482635
BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
Mar 27, 2018
Primary completion
May 18, 2020
Study completion May 18, 2020
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are * to prove the concept of clinical activity of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments and to identify efficacious and safe dose regimens in Part 1 (Phase II) * to confirm efficacy and safety of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments in Part 2 (Phase III) * To provide, along with induction study 1368-0018 and the run-in cohort of 1368-0020, the target population to be evaluated in study 1368-0020.
Conditions
- Colitis, Ulcerative
Interventions
SpesolimabDrug
Solution for infusion
PlaceboDrug
Solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients With Clinical Remission at Week 12Time frame: At week 12.
Locations
54 sites in 12 countries. Site status is shown where the registry gives one.
Medical Research Center of Connecticut, LLC
Hamden, Connecticut
University of Miami
Miami, Florida
AdventHealth Orlando
Orlando, Florida
Emory University
Atlanta, Georgia
Atlanta Center for Gastroenterology, P.C.
Decatur, Georgia
University of Chicago
Chicago, Illinois
Columbia University Medical Center-New York Presbyterian Hospital
New York, New York
University Hospitals of Cleveland
Cleveland, Ohio
Digestive Disease Specialists Inc
Oklahoma City, Oklahoma
Baylor College of Medicine
Houston, Texas
Southern Star Research Institute, LLC
San Antonio, Texas
Texas Digestive Disease Consultants - Southlake
Southlake, Texas
Hunter Holmes McGuire VA Medical Center
Richmond, Virginia
Ordensklinikum Linz GmbH - Barmherzige Schwestern
Linz, Austria
AKH - Medical University of Vienna
Vienna, Austria
UZ Leuven
Leuven, Belgium
Centre Hospitalier Universitaire de Liège
Liège, Belgium
University of Manitoba - Health Sciences Centre
Winnipeg, Manitoba, Canada
Victoria Hospital (LHSC)
London, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Universitätsklinikum Aachen, AöR
Aachen, Germany
Universitätsklinikum Erlangen
Erlangen, Germany
Universitätsklinikum Essen AöR
Essen, Germany
Klinikum Esslingen GmbH
Esslingen am Neckar, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, Germany
Universitätsklinikum Ulm
Ulm, Germany
Azienda Ospedaliera Universitaria di Padova
Padova, Italy
Istituto Clinico Humanitas
Rozzano (MI), Italy
Toho University Sakura Medical Center
Chiba, Sakura, Japan
Sapporo Tokushukai Hospital
Hokkaido, Sapporo, Japan
Sapporo Higashi Tokushukai Hospital
Hokkaido, Sapporo, Japan
Hyogo College of Medicine Hospital
Hyogo, Nishinomiya, Japan
Sameshima Hospital
Kagoshima, Kagoshima, Japan
Ofuna Chuo Hospital
Kanagawa, Kamakura, Japan
Tokyo Medical and Dental University
Tokyo, Bunkyo-ku, Japan
Kitasato Institute Hospital
Tokyo, Minato-ku, Japan
Tokyo Yamate Medical Center
Tokyo, Shinjuku, Japan
Health Center of Mother, Child and Youth Sp.z o.o.
Warsaw, Poland
Central Clinical Hospital MSWiA, Internal Diseases, Warsaw
Warsaw, Poland
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.